AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
188.89
-2.11 (-1.10%)
At close: 4:04PM EDT

188.89 0.00 (0.00%)
After hours: 5:15PM EDT

Stock chart is not supported by your current browser
Previous Close191.00
Open191.28
Bid0.00 x 800
Ask0.00 x 800
Day's Range187.68 - 191.81
52 Week Range142.81 - 197.00
Volume1,648,109
Avg. Volume1,832,713
Market Cap64.118B
Beta (3Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-5.32
Earnings DateOct 30, 2018
Forward Dividend & Yield2.88 (1.57%)
Ex-Dividend Date2018-08-16
1y Target Est214.16
Trade prices are not sourced from all markets
  • Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?
    Zacks2 days ago

    Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?

    Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.

  • MarketWatch2 days ago

    Allergan plans to file for U.S. approval of new migraine drug by Q1 of 2019

    Allergan PLC said early Wednesday that it plans to file for U.S. approval of its acute migraine drug, ubrogepant, by the first quarter of 2019. If all goes as expected, the company said it expects the drug will be "the first oral CGRP receptor antagonist submitted in the U.S. for the acute treatment of migraine with or without aura." A slew of new drugs have recently been approved to prevent migraine -- a chronic, debilitating condition that millions of Americans suffer from -- but Allergan's drug takes a different approach, and is intended to for so-called "acute relief," or easing the painful attacks as they occur. Existing alternatives in this space include general pain drugs and popular migraine medications called triptans. Allergan has previously said that it plans to file for Food and Drug Administration approval of ubrogepant next year; the recent completion of two clinical studies should allow it to file by the first quarter, the company said. Company shares rose 0.5% in Wednesday premarket trade. Shares have surged 7% over the last three months, compared with a 0.01% rise in the S&P 500 and a 2.7% rise in the Dow Jones Industrial Average .

  • PR Newswire2 days ago

    Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

    DUBLIN, Oct. 17, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine. Based on the completion of these safety studies for ubrogepant and previously reported efficacy and safety results from the ubrogepant ACHIEVE I (UBR-MD-01) and ACHIEVE II (UBR-MD-02). Allergan anticipates that the ubrogepant NDA will be the first oral CGRP receptor antagonist submitted in the U.S. for the acute treatment of migraine with or without aura.

  • Investopedia2 days ago

    5 Blue Chip Drug Stocks Poised for Long-Term Gains

    Big pharmaceutical stocks have routinely lagged those of the biotech sector and, so far this year, are underperforming the broader health-care sector by a margin of more than 7%. Citing fading headwinds along with innovation and boosted new-drug sales, Guggenheim’s Seamus Fernandez names Merck & Co. Inc. ( MRK), Allergan PLC ( AGN) and AstraZeneca ( AZN) as three of his favorites, while also giving Eli Lilly & Co. ( LLY) and Novo Nordisk ( NVO) a buy rating, according to Barron’s.

  • FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
    PR Newswire3 days ago

    FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

    DUBLIN and SAN FRANCISCO, Oct. 16, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for the prevention of pregnancy for up to five years. "A large and diverse population of women already use LILETTA as a safe, long-acting and reversible contraceptive option. This approval means that LILETTA is now indicated for up to 5 years of use.

  • PR Newswire7 days ago

    Allergan To Present Data From 13 Abstracts At The 2018 American Society For Dermatologic Surgery Meeting In Phoenix

    DUBLIN , Oct. 11, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 13 abstracts at the annual American Society for Dermatologic ...

  • Better Buy: Crispr Therapeutics AG vs. Editas
    Motley Fool9 days ago

    Better Buy: Crispr Therapeutics AG vs. Editas

    Which gene editing start-up has the best chance to outperform in the years ahead?

  • Allergan’s Neurology Portfolio, Stock Performance, and Ratings
    Market Realist10 days ago

    Allergan’s Neurology Portfolio, Stock Performance, and Ratings

    On October 3, Allergan’s (AGN) stock price closed at $193.46, which is ~11.0% below its 52-week high of $215.10 on October 3, 2017. Allergan’s stock price grew from $164.05 at the open of the market on January 2 to $193.46 on October 3, which reflects ~18.0% YTD (year-to-date) growth. On March 5, Merck hit its 52-week low of $142.81.

  • PR Newswire11 days ago

    Allergan Presents New Research at the American College of Gastroenterology Annual Scientific Meeting (ACG 2018)

    DUBLIN, Oct. 8, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced it will present data from its gastroenterology portfolio at the American College of Gastroenterology Annual Scientific Meeting (ACG), from October 5-10, 2018 in Philadelphia, PA. "Allergan is working to change treatment paradigms across gastroenterology with our Open Science research and development model," said David Nicholson, Chief Research and Development Officer, Allergan. Allergan will present efficacy and safety data from RELIEF, a Phase 4, multicenter, multinational, randomized, placebo-controlled, double-blind study of VIBERZI® (eluxadoline) CIV in patients with irritable bowel syndrome with diarrhea (IBS-D) who report inadequate symptom control with loperamide (poster #0344).

  • PR Newswire14 days ago

    Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

    - New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab - Programs are part of ...

  • Allergan’s Stock Performance and Estimates for Q3 2018
    Market Realist15 days ago

    Allergan’s Stock Performance and Estimates for Q3 2018

    Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.

  • PR Newswire15 days ago

    Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®

    DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced that the CoolSculpting® treatment received FDA clearance to treat the submandibular area. In addition, the FDA clearance was expanded to include patients with a BMI of up to 46.2 when treating the submental and submandibular areas. This recent clearance makes CoolSculpting® the first and only nonsurgical fat reduction treatment to contour the area below the jawline and improve the appearance of lax tissue in conjunction with submental fat treatments.

  • Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
    Market Realist15 days ago

    Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018

    The US Pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists the recent mergers and acquisitions in the pharmaceuticals sector.

  • Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara
    Zacks15 days ago

    Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara

    Paratek (PRTK) gets FDA approval for Nuzyra for the treatment of serious community-acquired bacterial infections and Seysara for the treatment of acne.

  • Health care just posted its best quarter in 5 years, but there's still value to be found says trader
    CNBC16 days ago

    Health care just posted its best quarter in 5 years, but there's still value to be found says trader

    Health care gained 14.04% in the third quarter, but traders say individual names within the space are under valued and poised to move higher.

  • Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers
    PR Newswire16 days ago

    Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers

    DUBLIN, Oct. 3, 2018 /PRNewswire/ -- Allergan plc (AGN) announced today the launch of a new JUVÉDERM® advertising campaign created to empower the next generation of consumers to "JUVÉDERM® IT." JUVÉDERM® IT marks the first new advertising campaign in three years for the world's #1 selling dermal filler collection1 and was designed to further Allergan's goal of making the JUVÉDERM® Collection of Fillers a first choice and household name for consumers.

  • Genentech's first scientist now focused on Bay Area's latest biotech IPO
    American City Business Journals17 days ago

    Genentech's first scientist now focused on Bay Area's latest biotech IPO

    Dave Goeddel helped build Genentech and Tularik and played a key role in building NGM's portfolio of drugs, including an experimental treatment for nonalcoholic steatohepatitis, or NASH.

  • PR Newswire18 days ago

    Allergan to Report Third Quarter 2018 Earnings and Host Conference Call and Webcast

    DUBLIN , Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018 , prior to the open of U.S. financial ...

  • What’s Eli Lilly’s Valuation as of September 27?
    Market Realist20 days ago

    What’s Eli Lilly’s Valuation as of September 27?

    Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue compared to $5.8 billion in the second quarter of 2017.

  • Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs
    Zacks20 days ago

    Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs

    FDA grants approval to Lilly's (LLY) Emgality for migraine and Pfizer's (PFE) Vizimpro for an advanced lung cancer indication. Novartis (NVS) to cut more than 2,000 jobs in Switzerland and U.K

  • PR Newswire21 days ago

    Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

    DUBLIN, Sept. 28, 2018 /PRNewswire/ -- In celebration of breast cancer awareness month, Allergan plc (AGN) announced today The Allergan Foundation's continuing commitment to breast health, awareness, restoration, and research through a $2,000,000 pledge to be paid over the next three years to select nonprofit organizations. Established in 1998, The Allergan Foundation is a U.S.-based, private charitable foundation committed to providing a lasting and positive impact in the communities in which Allergan employees live and work.  The Allergan Foundation focuses its support on charitable efforts dedicated to promoting access to quality healthcare and improving patient diagnosis, treatment, care and quality of life.  The Allergan Foundation has donated more than $84 million to charities, both domestic and abroad, since its inception.  Individuals interested in learning more about The Allergan Foundation can visit AllerganFoundation.org.

  • Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA
    Zacks21 days ago

    Allergan Eyes Vraylar Label Expansion, FDA Accepts sNDA

    FDA accepts Allergan's (AGN) sNDA for label expansion of its schizophrenia drug, Vraylar (cariprazine) to include treatment of bipolar depression.

  • Allergan’s SpotLyte and Lumivive System
    Market Realist23 days ago

    Allergan’s SpotLyte and Lumivive System

    On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System. SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

  • A Closer Look at the Allergan–Bonti Deal
    Market Realist23 days ago

    A Closer Look at the Allergan–Bonti Deal

    On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company. Bonti is a privately held company focused on developing and commercializing the neurotoxin programs for use in aesthetics and therapeutics. The chart below shows the highlights of the deal.